Amanda Nizam, MD

Amanda Nizam, MD, is a GU medical oncologist at the Cleveland Clinic, specialized in treating bladder, kidney, and prostate cancer.

Articles by Amanda Nizam, MD

Shilpa Gupta, MDAdvanced Urothelial Carcinoma | July 16, 2024
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
View More
Michiel van der Heijden, MD, PhDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
Antonio Cigliola, MDMuscle Invasive Urothelial Carcinoma | June 6, 2024
Drs. Cigliola and Nizam discuss the implications of the reported SURE-01/02 study interim results.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Matthew Galsky, MDAdvanced Urothelial Carcinoma | June 6, 2024
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 28, 2024
Drs. Koshkin and Nizam discuss the trastuzumab deruxtecan FDA approval and the DESTINY-PanTumor02 clinical trial.
Vadim Koshkin, MDUrothelial Carcinoma | February 12, 2024
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 20, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 20, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | May 20, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
Amanda Nizam, MDAdvanced Urothelial Carcinoma | November 20, 2023
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
Thomas Powles, MBBS, MRCP, MDUromigos Live 2023 | November 14, 2023
Drs. Powles and Nizam discuss her strategy of intensifying treatment upfront in oligometastatic urothelial carcinoma.
Amanda Nizam, MDUromigos Live 2023 | November 8, 2023
Amanda Nizam, MD, discusses her proposed trial examining EV and pembrolizumab in patients with oligometastatic UC.